ABSTRACT
Silymarin is considered to be the gold standard in the treatment of the liver diseases. However, poor bioavailability of silymarin is a limiting factor and as a result nanosilymarin has been developed. Silymarin nanoparticles were strongly protective against hepatic damage when tested in a paracetamol overdose hepatotoxicity model. The silybin nanosuspensions, administrated either intravenously or orally, presented significant (P < or = 0.05) hepatoprotective effect by reducing the serum marker enzymes such as AST, ALT, ALP, TBIL and GGT. Silymarin-loaded solid lipid nanoparticle significantly reduced D-GaIN/TNF-/-induced hepatotoxicity, which suggested improved bioactivity compared to silymarin. Co-administration of silymarin and nano- selenium with a good antioxidant profile and inhibition of NF-Ϋ is a possible candidate for better management of inflammatory bowel disease.
